Mast cell activation syndrome: possibilities for pharmacotherapy
Abstract
About a century and a half has passed since Paul Ehrlich first described mast cells, but even today, in-depth study of the functions of mast cells continues, detailing their participation both in maintaining health and elucidating their role in various pathological conditions. Modern advances in mast cell research have strengthened the understanding that mast cells have unique immune functions, a better understanding of which will have a major impact on human health. There is increasing evidence of their participation in the pathogenesis of not only allergic, but also other diseases, including SARS-CoV-2 infection, psoriasis, myalgic encephalomyelitis, multiple sclerosis, diseases of the digestive system, rheumatoid arthritis, interstitial cystitis, tumor development, cardiovascular vascular diseases and other pathologies associated with chronic inflammation. Modem data on the function of mast cells, their primary and secondary dysfunction, including mast cell activation syndrome, require a new analytical approach - a new worldview. The potential of mast cells and their numerous mediators as therapeutic targets and biomarkers of disease severity and treatment outcome has been actively discussed in the recent literature, which is consistent with the principles of precision medicine.
References
1. Cookson H., Grattan C. An update on mast cell disorders. Clin. Med. (Lond). 2016; 16: 580-3.
2. Moon T. C., Befus A. D., Kulka M. Mast cell mediators: their differential release and the secretory pathways involved. Front. Immunol. 2014: 5: 569.
3. Vliagoftis H., Befus A. D. Rapidly changing perspectives about mast cells at mucosal surfaces. Immunol. Rev. 2005; 206: 190 203.
4. Mekori Y. A., Metcalfe D. D. Mast cells in innate immunity. Immunol. Rev. 2000; 173: 131-40.
5. Akin C. Mast cell activation disorders. J. Allergy Clin. Immunol. Pract. 2014; 2: 252-7.e1.
6. Yu L. C., Perdue M. H. Role of mast cells in intestinal mucosal function:studies in models of hypersensitivity and stress. Immunol. Rev. 2001; 179: 61 -73.
7. Bischoff S. C. Physiological and pathophysiological functions of intestinal mast cells. Semin. Immunopathol. 2009: 31: 185 205.
8. Varricchi G., De Paulis A., Marone G., Galli S. J. Future needs in mast cell biology. Int. J. Mol. Sci. 2019; 20: 4397.
9. Theoharides T., Tsilioni I., Ren H. Recent advances in our understanding of mast cell activation: or should it be mast cell mediator disorders? Expert Rev. Clin. Immunol. 2019; 15: 639 56.
10. Rivellese F., Rossi F. W., Galdiero M. R. et al. Mast cells in early rheumatoid arthritis. Int. J. Mol. Med. 2019; 20: 1-13.
11. Ragipoglu D., Dudeck A., Haffner-Luntzer M. et al. The role of mast cells in bone metabolism and bone disorders. Front. Immunol. 2020: 11: 163.
12. Sprinzl B., Greiner G., Uyanik G. et al. Genetic regulation of tryptase production and clinical impact: hereditary alpha tryptasemia, mastocytosis and beyond. Int. J. Mol. Sci. 2021: 22: 2458.
13. Bagher M., Larsson-Callerfelt A. K., Rosmark O. et al. Mast cells and mast cell tryptase enhance migration of human lung fibroblasts through protease-activated receptor 2. Cell. Commun. Signal. 2018; 16: 59.
14. Desai A., Jung M. Y., Olivera A. etal. IL-6 promotes an increase in human mast cell numbers and reactivity through suppression of suppressor of cytokine signaling 3. J. Allergy Clin. Immunol. 2016; 137: 1863 71.
15. Hallgren J., Pejler G. Biology of mast cell tryptase. An inflammatory mediator. FEBS J. 2006; 273: 1871 95.
16. Schwartz L. B., Min H. K., Ren S. et al. Tryptase precursors are preferentially and spontaneously released, whereas mature tryptase is retained by HMC-1 cells, Mono-Mac-6 cells, and human skin-derived mast cells. J. Immunol. 2003; 170: 5667-73.
17. Schwartz L. B. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol. Allergy Clin. North Am. 2006; 26: 451-63.
18. Cildir G., Pant H., Lopez A. F., Tergaonkar V. The transcriptional program, functional heterogeneity, and clinical targeting of mast cells. J. ExpMed. 2017; 214 (9): 2491-506 .
19. Ustun C., Arock M., Kluin-Nelemans H. C. et al. Advanced systemic mastocytosis: From molecular and genetic progress to clinical practice. Haematologica. 2016; 101: 1133 43.
20. Valent P., Akin C., Hartmann K. et al. Advances in the classification and treatment of mastocytosis: Current status and outlook toward the future. Cancer Res. 2017: 77: 1261…70.
21. Voehringer D. Protective and pathological roles of mast cells and basophils. Nat. Rev. Immunol. 2013; 13: 362 75.
22. Galli S. J., Borregaard N., Wynn T. A.… Phenotypic and functional plasticity of cells of innate immunity: Macrophages, mast cells and neutrophils. Nat. Immunol. 2011; 12:10354 5 44.
23. Wernersson S., Pejler G. Mast cell secretory granules: Armed for battle. Nat. Rev. Immunol. 2014; 14: 478 94.
24. Abraham S. N., St. John A. L. Mast cell-orchestrated immunity to pathogens. Nat. Rev. Immunol. 2010; 10: 440 52.
25. Lam H. Y., Tergaonkar V., Kumar A. P., Ahn K. S. Mast cells: Therapeutic targets for COVID-19 and beyond. IUBMBLife. 2021; 73 (11): 1278 92.
26. Galli S. J., Gaudenzio N., Tsai M. Mast cells in inflammation and disease: recent progress and ongoing concems. Ann. Rev. Immunol. 2020; 38: 49 77.
27. Weiler C. R., Austen K. F., Akin C. et al. AAAAI Mast Cell Disorders Committee Work Group Report: Mast cell activation syndrome (MCAS) diagnosis and management. J. Allergy Clinimmunol. 2019; 144 (4): 883 96.
28. Valent P. Mast cell activation syndromes:definition and classification. Allergy. 2013; 68: 417 24.
29. Lee M. J, Akin C. Mast cell activation syndromes. Ann. Allergy Asthma Immunol. 2013; 111: 5 8.
30. Picard M., Giavina-Bianchi P., Mezzano V., Castells M. Expanding spectrum of mast cell activation disorders:monoclonal and idiopathic mast cell activation syndromes. Clin. Ther. 2013; 35: 548 62.
31. Akin C. Mast cell activation syndromes. J. Allergy Clin. Immunol. 2017: 140: 349 55.
32. Frieri M. Mast cell activation syndrome. Clin. Rev. Allergy Immunol. 2018; 54: 353 65.
33. Valent P., Akin C., Arock M. et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int. Arch. Allergy Immunol. 2012; 157: 215 25.
34. Kritas S. K., Ronconi G., Caraffa Al. et al. Mast cells contribute to coronavirus-induced inflammation: new anti-inflammatory strategy. J. Biol. Regul. Home ost Agents 2020; 34 (1): 9 14.
35. Motta J. J., Miggiolaro A. F., Nagashima S. et al. Mast cells in alveolar septa of COVID-19 patients: a pathogenic pathway that may link interstitial edema to immunothrombosis. Front. Immunol. 2020; 11: 574862.
36. Zhou Z., Ren L., Zhang L., et al. Heightened innate immune responses in the respiratory tract of COVID-19 patients. Cell Host Microbe. 2020; 27: 883 890.e2.
37. Gebremeskel S., Schanin J., Coyle K. M. et al. Mast cell and eosinophil activation are associated with COVID-19 and TLR-mediated viral inflammation: implications for an anti-siglec-8 antibody. Front. Immunol. 2021; 12: 1-12.
38. Tan J., Anderson D. E., Rathore A. P. et al. Signatures of mast cell activation are associated with severe COVID-19. medRxiv. 2021: 21255594.
39. Xu Y., Chen G. Mast cell and autoimmune diseases. Mediators Inflamm. 2015; 246126.
40. Tetlow L., Woolley D. Mast Cells, Cytokines, and Metalloproteinases at the Rheumatoid Lesion: Dual. Immunolocalisation Studies. Ann. Rheum. Dis. 1995; 54 (11): 896 903.
41. Gotis-Graham I., Smith M. D., Parker A., McNeil H. P. Synovial mast cell responses during clinical improvement in early rheumatoid arthritis. Ann. Rheum. Dis. 1998; 57 (11): 664 71.
42. Kim K. W., Kim B. M., Won J. Y. et al. Regulation of Osteoclastogenesis by Mast Cell in Rheumatoid Arthritis. Arthritis Res. Ther. 2021; 23 (1): 124.
43. Rivellese F., Mauro D., Nerviani A. et al. Mast cells in early rheumatoid arthritis associate with disease severity and support B cell autoantibody production. Ann. Rheum. Dis. 2018; 77 (12): 1773 81.
44. Vasilevsky I.V. The role of mast cells in diseases of the gastrointestinal tract in children. Materials of the 28th Congress of Pediatric Gastroenterologists of Russia and the CIS Countries «Current Problems of Abdominal Pathology in Children». Moscow, March 23-25, 2021. M.: ID «MEDPRACTIKA-M», 2021. p. 13 -15. [(in Russian)]
45. Bischoff S. C., Kramer S. Human mast cells, bacteria, and intestinal immunity. Immunol. Rev. 2007; 217: 329 -37.
46. Vasilevsky I. V. Modern approaches to understanding the essence of eosinophilic esophagitis. Meditsinskie novosti. 2021; 8: 27 32. [(in Russian)]
47. Vasilevsky I. V. Molecular pathophysiological mechanisms of allergic esophagitis. Materials of the Anniversary XXX Congress of Pediatric Gastroenterologists of Russia and the CIS Countries «Current Problems of Abdominal Pathology in Children». M.: Publishing House «Medpraktika-M», 2023. p. 119 21. [(in Russian)]
48. Yeom J. S., Buchowski J. M., Kim H. J. et al. Risk of vertebral artery injury: comparison between C1-C2 transarticular and C2 pedicle screws. Spine J. 2013; 13 (7): 775 85.
49. Wu C., Chen X., Cai Y. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020; 180 (7): 934 43.
50. Czamy J., Lange M., Lugowska-Umer H., Nowicki R. J. Cutaneous mastocytosis treatment: strategies, limitations and perspectives. Postepy Dermatol. Alergol. 2018; 35 (6): 541-5.
51. Siebenhaar F., Sander B., Ho L.H. et al. Development and validation ofthe mastocytosis activity score. Allergy. 2018; 73 (7): 1489 -96.
52. Kiwamoto T., Kawasaki N., Paulson J. C., Bochner B. S. Siglec-8 as a drugable target to treat eosinophil and mast cellassociated conditions. Pharmacol. Ther. 2012: 135: 32736.
53. Mizrahi S., Gibbs B.F., Karra L. et al. Siglec-7 is an inhibitory receptor on human mast cells and basophils. J. Allergy Clin. Immunol. 2014; 134: 230 -233.e3.
54. Burchett J. R., Dailey J. M., Kee S. A. et al. Targeting Mast Cells in Allergic Disease: Current Therapies and Drug Repurposing. Cells. 2022; 11: 3031.
55. Baran J., Sobiepanek A., Mazurkiewicz-Pisarek A. et al. Mast cells as a target - a comprehensive review ofrecent therapeutic approaches. Cells. 2023; 12 (8): 1187.
56. Wilcock A., Bahri R., Bulfone-Paus S., Arkwright P. D. Mast cell disorders: From infancy to maturity. Allergy. 2019: 74 (Issue 1): 53 63.
57. Mikryukova N. V., Kalinina N. M. Mast cell activation syndrome: a new world view. Meditsinskaya immunologiya. Available at: https: // doi.org/10.15789/1563-0625-MCA-2662. [(in Russian)]
Review
For citations:
Vasilevsky I.V. Mast cell activation syndrome: possibilities for pharmacotherapy. Healthcare. 2023;(12):24-35. (In Russ.)
Views:
10
Email this article 